Shire Opens Tokyo Office, Strengthens Japanese Presence
This article was originally published in PharmAsia News
Executive Summary
British specialty drug maker Shire Feb. 23 opened a representative office in Tokyo. The company appointed former Genzyme Japan executive Soh Fujiwara as managing director. Shire's Hunter syndrome drug Elaprase (idursulfase) is marketed currently in Japan through collaboration with Genzyme. With the opening of the Tokyo office, the company aims to introduce specialty drugs to treat inflammatorily bowel disease, hyperphosphatemia and Fabry's disease to Japan. The Tokyo office is Shire's third office in the Asia-Pacific region, after Singapore and Australia. (Click here for more - Japanese language
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.